Public Health Vaccines has initiated a Phase 1 clinical trial for a novel vaccine candidate, PHV01, which targets the Marburg virus.

Theratechnologies Inc., has progressed to a higher dosage level in the third phase of its clinical trial for a drug called sudocetaxel zendusortide.

Blue Lake Biotechnology has released early findings from a Phase 1/2a clinical trial for BLB201.

Andelyn Biosciences has teamed up with Grace Science, LLC, to facilitate the technical transfer and production of GS-100, an AAV NGLY1 gene therapy for clinical trials.

Brain Trust Bio (BTB), a pioneering company in the field of central nervous system (CNS) disease treatment, has been granted the go-ahead to initiate Phase I clinical trials.

Astria Therapeutics has reported promising preliminary results from the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215.

Stoke Therapeutics has reported significant findings from its Phase 1/2a clinical trials and open-label extension studies for STK-001.

Rhythm Pharmaceuticals has commenced dosing for its Phase 1 clinical trial of RM-718.

Valneva SE launched a Phase 1 clinical study to evaluate the safety and ability to provoke an immune response of their Zika virus vaccine candidate, VLA1601.

Tectonic Therapeutic has commenced a Phase 1B clinical trial for TX45, a novel long-acting relaxin-Fc fusion protein.

Viking Therapeutics has reported significant weight loss outcomes from a Phase 1 clinical trial of VK2735, a new dual GLP-1/GIP receptor agonist.

CIN-110 is being developed by CinFina Pharma, a company within the CinRx portfolio that focuses on treatments for obesity and metabolic disorders.